Caprine Arthritis Encephalitis (CAE)

Caprine arthritis encephalitis (CAE) is a chronic, progressive viral disease of goats caused by the caprine arthritis encephalitis virus (CAEV), a lentivirus within the Retroviridae family. This disease is closely related to ovine progressive pneumonia (maedi-visna) in sheep, and together these viruses are often referred to as small ruminant lentiviruses. CAE is characterized by persistent infection that develops slowly over months to years, eventually causing debilitating clinical disease in a proportion of infected animals. The disease takes multiple forms, including arthritis in adult goats, encephalitis in young kids, mastitis affecting milk production, and chronic pneumonia resembling the presentation in sheep.

Caprine arthritis encephalitis occurs worldwide wherever goats are raised, with prevalence varying significantly between regions and management systems. Seroprevalence studies indicate that CAE is particularly common in intensive dairy goat operations, where management practices favor transmission through pooled colostrum and milk feeding. Prevalence can exceed 80 percent in some dairy herds, while extensively managed meat goat operations may have much lower infection rates. The virus has been identified in nearly all goat breeds, and while sheep can be experimentally infected with CAEV, natural transmission to sheep appears uncommon though possible.

The economic and welfare impact of CAE is substantial for affected goat operations. Arthritic goats suffer chronic pain and progressive lameness that eventually impairs mobility and quality of life. Milk production in infected dairy does is reduced compared to uninfected herdmates, with studies demonstrating 10 to 15 percent lower milk yields. Mastitis associated with CAE produces a characteristic hard udder that further compromises milk production and may complicate machine milking. Premature culling of productive animals due to progressive disease represents significant economic loss. Encephalitis in valuable young stock causes death or permanent neurological damage.

Early detection of CAE through testing and implementation of control programs can significantly reduce disease prevalence within herds. While no cure or vaccine is available, management practices that interrupt transmission from infected dams to offspring can progressively reduce herd prevalence over time. Testing and culling programs, along with careful colostrum and milk management, form the foundation of CAE control. Understanding the persistent, lifelong nature of infection and the multiple routes of transmission is essential for developing effective herd management strategies that protect goat health and productivity.

Caprine arthritis encephalitis virus (CAEV) is a lentivirus belonging to the Retroviridae family, characterized by its ability to integrate into host cell DNA and establish persistent, lifelong infection. The virus is closely related to maedi-visna virus of sheep, and together they are classified as small ruminant lentiviruses (SRLVs). CAEV is an enveloped RNA virus that uses reverse transcriptase to convert its RNA genome into DNA, which then integrates into the chromosomes of infected cells. This integration allows the virus to persist indefinitely despite host immune responses, as infected cells pass viral DNA to their progeny during cell division.

Genetic and breed predisposition to CAE clinical disease has not been definitively established, though some evidence suggests breed-related differences in susceptibility and disease expression. Swiss dairy breeds including Saanen, Alpine, and Toggenburg appear to be commonly affected, though this may reflect the intensive management practices used in dairy operations rather than true genetic susceptibility. Some studies suggest that certain genetic backgrounds may influence the likelihood of developing clinical disease following infection. Nigerian Dwarf and other miniature breeds have shown high seroprevalence in some surveys. Meat goat breeds raised extensively may have lower prevalence due to management factors rather than genetic resistance.

Environmental and management factors play crucial roles in CAE transmission dynamics within goat herds. The primary route of transmission is through ingestion of infected colostrum and milk by kids, making colostrum management practices the most important determinant of kid infection rates. Horizontal transmission between adult goats can occur through direct contact with infected secretions including respiratory droplets, though this appears less efficient than lactogenic transmission. Housing systems that allow close contact between infected and susceptible animals facilitate transmission. Shared milking equipment without adequate sanitation between animals may contribute to spread.

Risk factors for CAE infection center on exposure to virus-containing fluids, particularly from dam to offspring. Kids nursing CAE-positive dams or fed pooled colostrum from infected herds have high infection rates, with studies showing 70 to 90 percent of kids becoming infected through this route. Prolonged close contact between infected and uninfected adult goats allows horizontal transmission to occur over time. Introduction of infected animals to naive herds represents a primary source of new infections. In utero transmission appears possible but uncommon. Using unscreened breeding bucks from infected herds introduces infection risk, as virus may be present in semen though this route is considered less important than lactogenic transmission.

The pathophysiology of CAE involves viral infection of monocytes and macrophages, with the virus remaining latent in circulating blood cells and becoming active when these cells differentiate into tissue macrophages. The immune response to the virus paradoxically contributes to tissue damage, as the inflammatory response in joints, brain, lungs, and udder causes the clinical manifestations of disease. In joints, chronic inflammation leads to synovial hyperplasia, cartilage destruction, and periarticular fibrosis. In the brain of young kids, viral infection of glial cells causes demyelination and neuronal damage. In the udder, interstitial mastitis with lymphoid infiltration reduces secretory tissue. The prolonged incubation period reflects the slow accumulation of immune-mediated damage over months to years.

Early warning signs of CAE in goats are often subtle and easily overlooked, as the disease typically develops slowly over extended periods. Adult goats may show mild stiffness or reluctance to rise that progresses so gradually that owners attribute changes to aging rather than disease. Careful observation may reveal slight swelling around the carpus or other joints that worsens over time. Kids with the encephalitic form may show subtle behavioral changes or weakness before obvious neurological signs develop. Dairy goats may show gradual decline in milk production that is attributed to other factors. Early identification requires awareness of CAE risk and willingness to investigate subtle changes.

Common symptoms of CAE vary depending on which clinical form develops, though multiple forms may occur in the same animal. The arthritic form, most common in adult goats over one to two years of age, produces progressive joint swelling, particularly affecting the carpus (knee), though any joint can be involved. Affected joints become enlarged, firm, and eventually painful, leading to lameness and reluctance to move. The encephalitic form occurs primarily in kids between two and four months of age and produces ascending paralysis beginning in the hindlimbs and progressing to involve all four limbs. The mastitic form causes a firm, non-painful udder with reduced milk production, commonly called hard udder. The pneumonic form causes chronic respiratory disease similar to ovine progressive pneumonia.

Behavioral changes in CAE-affected goats reflect the discomfort and disability caused by progressive disease. Goats with arthritis become increasingly reluctant to move, stand for shorter periods, and may have difficulty rising from lying positions. Affected animals often lag behind the herd and avoid interactions that require movement. Kids with encephalitis show progressive weakness and may appear clumsy before obvious paralysis develops. Affected animals may separate from the group and spend more time resting. Appetite typically remains normal until disease becomes severe, though difficulty accessing feed or water due to mobility problems can lead to weight loss.

Physical signs of CAE reflect the multi-system nature of the disease. Joint swelling in the arthritic form is typically bilateral and may be warm in early stages, becoming firm and cool as chronic changes develop. Range of motion becomes progressively restricted as periarticular fibrosis develops. Muscle wasting around affected joints occurs secondary to disuse. The udder in mastitic animals is firm and lacks the normal soft, pliable texture, with asymmetry common when one half is more severely affected. Respiratory signs in the pneumonic form include increased respiratory rate, coughing, and exercise intolerance. General body condition often deteriorates as the disease progresses due to difficulty maintaining feed intake.

Symptom progression in CAE follows different timelines depending on the clinical form. The encephalitic form in kids progresses rapidly over one to three weeks from initial weakness to complete paralysis and typically results in death or euthanasia. The arthritic form progresses much more slowly, often over years, with gradual worsening of joint enlargement, lameness, and disability. Many infected goats never develop clinical disease, remaining asymptomatic carriers throughout their lives. Animals with clinical disease may have periods of apparent stability interrupted by episodes of worsening. Once significant joint damage has occurred, progression to severe disability is typical even with supportive care.

Emergency symptoms requiring immediate veterinary attention include kids showing rapid neurological deterioration with paralysis affecting multiple limbs or respiratory function. Adult goats unable to rise due to severe arthritis pain or joint damage require urgent assessment and pain management. Signs of aspiration pneumonia in recumbent animals indicate life-threatening complications. Goats showing severe respiratory distress from the pneumonic form need immediate evaluation. Any affected animal that stops eating or drinking requires prompt intervention. Making humane euthanasia decisions for severely affected animals is often necessary, as CAE is incurable and progressive.

Clinical examination provides important diagnostic information for CAE, though definitive diagnosis requires laboratory testing. Veterinary assessment of goats with suspected CAE includes evaluation of joint size, shape, and range of motion, with comparison between affected and unaffected joints. Neurological examination of kids with suspected encephalitis assesses reflexes, proprioception, and muscle strength. Udder palpation identifies the firm texture characteristic of CAE mastitis. Auscultation of lungs may reveal abnormal sounds in animals with pneumonic disease. The combination of progressive joint swelling with normal or minimally elevated temperature, particularly in multiple animals within a herd, strongly suggests CAE.

Laboratory diagnostic testing for CAE relies primarily on serological detection of antibodies to the virus, as infected animals develop antibodies that persist throughout their lives. Enzyme-linked immunosorbent assay (ELISA) testing is the most commonly used screening method, offering good sensitivity and specificity for detecting CAE antibodies in serum or milk. Agar gel immunodiffusion (AGID) testing is considered highly specific and may be used to confirm positive ELISA results. Polymerase chain reaction (PCR) testing can detect viral nucleic acid in blood cells, providing direct evidence of infection independent of antibody response. PCR is particularly valuable for testing young kids before maternal antibodies have cleared and the animal's own antibody response has developed.

Serological testing interpretation requires understanding of antibody dynamics following infection. Kids that ingest infected colostrum acquire passive maternal antibodies that may persist for several months, potentially causing false-positive results in young animals. Testing kids before colostrum ingestion or after maternal antibodies have waned (typically by four to six months of age) provides more reliable results. Seroconversion following natural infection typically occurs within two to eight weeks but may take longer in some animals. Periodic retesting of seronegative animals in infected herds helps identify new infections. Testing before breeding decisions ensures that infected animals are not used for breeding.

Differential diagnosis for CAE depends on which clinical form is present. For the arthritic form, other causes of joint swelling and lameness must be considered, including mycoplasma arthritis, bacterial septic arthritis, trauma, and degenerative joint disease. The encephalitic form must be differentiated from other causes of neurological disease in kids including listeriosis, polioencephalomalacia, copper deficiency, and brain abscess. For the mastitic form, bacterial mastitis and other causes of abnormal udder texture should be considered. The pneumonic form resembles caseous lymphadenitis with pulmonary involvement, bacterial pneumonia, and lungworm infection.

Herd-level diagnostic approaches are essential for understanding CAE status and implementing control programs. Whole-herd serological testing identifies all infected animals and establishes baseline prevalence. Annual testing monitors progress of control programs and identifies new infections. Testing all animals before sale or purchase prevents inadvertent spread between herds. Bulk milk testing can provide preliminary screening information for dairy herds. Necropsy examination of animals culled for suspected CAE reveals characteristic pathological changes including chronic synovitis with lymphoid hyperplasia, interstitial pneumonia, and leukoencephalomalacia in kids. Combining individual testing with herd-level surveillance enables comprehensive disease characterization.

Emergency treatment for severe CAE manifestations focuses on supportive care and pain management, as no curative treatments exist. Kids with acute encephalitis require nursing care including maintenance of hydration, assistance with feeding, protection from injury, and comfortable bedding. Adult goats unable to rise due to severe arthritis need assistance standing, protection from environmental stressors, and soft bedding to prevent pressure sores. Pain management is essential for maintaining quality of life in severely affected animals. Moving affected animals to hospital pens separate from the main herd reduces stress and facilitates care.

Medical management of CAE relies entirely on supportive and symptomatic approaches, as no antiviral treatments are available for lentivirus infections. Non-steroidal anti-inflammatory drugs (NSAIDs) including meloxicam and flunixin provide pain relief and reduce inflammation in arthritic joints. These medications must be used according to veterinary prescription with attention to appropriate withdrawal times in animals intended for food production. Corticosteroids may provide temporary relief but have significant side effects with long-term use and are generally not recommended. Nutraceuticals including glucosamine and chondroitin sulfate may provide supportive benefit for joint health, though evidence in goats is limited.

Surgical intervention for CAE is limited in scope and application. Arthrocentesis (joint tap) may temporarily relieve pressure in severely swollen joints, though fluid typically reaccumulates. Surgical debridement or joint fusion has been attempted in valuable animals but outcomes are generally poor due to the progressive nature of the underlying disease. Most surgical considerations involve humane euthanasia decisions for severely affected animals rather than therapeutic interventions. The progressive, incurable nature of CAE means that surgical approaches offer little long-term benefit.

Supportive care for CAE-affected goats aims to maintain quality of life as long as possible within humane limits. Providing easy access to feed and water reduces the effort required for arthritic animals to maintain nutrition. Soft bedding cushions painful joints and prevents pressure sores in recumbent animals. Housing affected animals in protected areas reduces environmental stress. Hoof trimming maintains proper foot conformation and reduces additional strain on damaged joints. Separating affected animals from aggressive herdmates prevents injuries. Weight management through appropriate nutrition helps reduce stress on compromised joints.

Herd management during CAE control programs focuses on preventing transmission rather than treating infected individuals. Identifying and segregating seropositive animals prevents ongoing transmission to susceptible herdmates. Implementing protocols for colostrum and milk management interrupts the primary dam-to-kid transmission route. Testing programs identify infected animals for management decisions. Record keeping tracks infection status and enables informed breeding and culling decisions. Coordinating testing with breeding schedules ensures that only seronegative animals contribute to replacement stock.

Treatment decisions for CAE-positive goats must balance individual animal welfare against practical realities and herd health goals. Seropositive animals without clinical signs may remain productive for years and can be retained with management to prevent transmission to susceptible animals. Animals with mild to moderate arthritis may maintain acceptable quality of life with supportive care for extended periods. However, progressive disease eventually leads to severe disability that compromises welfare beyond what supportive care can address. Establishing clear criteria for humane euthanasia ensures that affected animals do not suffer unnecessarily. Valuable animals may warrant more intensive management efforts, while commercial animals with poor prognosis may be better served by earlier euthanasia decisions.

Recovery timeline for CAE is fundamentally different from acute diseases because infection is lifelong and clinical disease is progressive. Animals infected with CAEV never clear the virus, which persists through integration into host cell DNA. Clinical disease, once established, does not resolve but continues to progress, though the rate of progression varies considerably between individuals. Some infected goats never develop clinical disease during their natural lifespan, while others progress rapidly to severe disability. The concept of recovery does not apply in the traditional sense; rather, management focuses on maintaining quality of life for as long as possible.

Post-treatment care and monitoring for CAE-positive goats requires ongoing assessment of disease progression and quality of life. Regular evaluation of joint swelling, range of motion, and lameness helps track disease progression in arthritic animals. Monitoring body condition, appetite, and activity levels identifies animals whose quality of life may be declining. Periodic reassessment of pain management strategies ensures adequate comfort. Documentation of disease progression informs decisions about continued management versus humane euthanasia. Ongoing testing of herdmates identifies additional infected animals for management.

Prognosis for CAE depends on multiple factors including which clinical form develops, rate of disease progression, and management resources available. Many seropositive goats never develop clinical disease and live normal productive lifespans. Goats with mild arthritic changes may remain functional for years with appropriate management. Kids with encephalitis have poor prognosis, with most dying or requiring euthanasia within weeks of clinical onset. Animals with advanced arthritis eventually progress to severe disability requiring euthanasia on welfare grounds. The pneumonic and mastitic forms progress at variable rates but compromise productivity and quality of life over time.

Return to production considerations for CAE-positive goats must account for both individual animal productivity and herd health implications. Infected dairy does can continue producing milk but typically produce less than uninfected herdmates and may have hard udders that complicate milking. Seropositive animals should not be used for breeding if the goal is to reduce herd prevalence, as their offspring are at high risk of infection through colostrum and milk. Infected meat goats may reach market weight but may be culled earlier than planned if clinical disease develops. Milk from infected animals should not be fed to kids being raised as CAE-negative replacements. The fundamental consideration is that infected animals remain sources of infection throughout their lives.

Vaccination protocols for CAE do not exist, as no effective vaccine has been developed despite considerable research effort. The characteristics of lentivirus infections, including viral integration into host DNA, genetic variability, and immune evasion mechanisms, make vaccine development challenging. Research continues on potential vaccine approaches, but none are currently available for commercial use. Prevention therefore relies entirely on management practices that interrupt transmission routes and testing programs that identify infected animals for removal or segregated management.

Biosecurity measures for CAE focus on preventing introduction of infection to naive herds and interrupting transmission within infected herds. Maintaining closed herds without animal introductions eliminates the primary source of new infections. When purchases are necessary, requiring negative CAE testing before acquisition and retesting after a quarantine period reduces introduction risk. Avoiding shared equipment, facilities, and common grazing with herds of unknown status prevents inadvertent exposure. Testing breeding bucks before use and avoiding use of semen from infected males prevents venereal transmission. Careful management of colostrum and milk feeding interrupts the primary dam-to-kid transmission route.

Nutritional prevention for CAE does not prevent infection but supports overall health and immune function in goats. Maintaining appropriate nutrition helps infected animals maintain body condition and productivity for longer periods before clinical disease develops. Ensuring adequate trace mineral nutrition supports immune function and general health. Avoiding nutritional stress reduces factors that might accelerate disease progression. Good nutrition during pregnancy and lactation supports dam health and milk quality, though milk from infected dams should not be fed to kids in control programs.

Management practices for CAE prevention center on breaking the dam-to-kid transmission cycle and managing infected animals appropriately. Kids at risk should be removed from dams immediately at birth before nursing occurs. Heat-treating colostrum to 56 degrees Celsius for 60 minutes inactivates CAEV while preserving immunoglobulin function, though protocols must be carefully followed to avoid colostrum damage. Feeding pasteurized milk or milk replacer instead of raw infected milk prevents lactogenic transmission. Raising kids separately from infected adults until they can be tested and confirmed negative protects their status. Testing all breeding animals and using only seronegative animals for breeding progressively reduces herd prevalence.

Quarantine and testing protocols are essential components of CAE prevention programs. All new animals entering the herd should be tested and confirmed negative before joining the main herd, ideally with retesting after a quarantine period to detect recently infected animals that may not yet have seroconverted. Regular annual testing of the entire herd identifies new infections for management. Testing animals before breeding ensures that only seronegative animals are used for reproduction. Kids raised for CAE-negative status should be tested at four to six months of age after maternal antibodies have waned. Working with veterinarians experienced in CAE control helps design testing programs appropriate for individual herd goals and resources.

Daily management and monitoring for herds addressing CAE requires consistent attention to animal health, herd segregation, and transmission prevention. Observing animals daily for signs of lameness, joint swelling, or respiratory problems enables early identification of clinical disease. Maintaining accurate records of individual animal CAE status guides management decisions and informs breeding programs. Monitoring kid health during the critical period from birth through weaning identifies encephalitis cases early. Tracking milk production helps identify mastitic animals whose production is declining. Consistent application of transmission prevention protocols ensures that control programs achieve their goals.

Housing and environmental management influence both CAE transmission and quality of life for affected animals. Separate housing or pasture for CAE-positive and negative animals prevents ongoing transmission. Adequate space reduces crowding stress and competitive pressure on animals with mobility limitations. Soft footing and bedding cushions arthritic joints and prevents injury to compromised animals. Easy access to feed and water reduces the effort required for disabled animals to maintain nutrition. Climate control appropriate to the region prevents temperature stress that may exacerbate clinical signs. Proper ventilation is particularly important for animals with respiratory involvement.

Herd health programs addressing CAE integrate testing, management, and monitoring into comprehensive approaches tailored to herd goals. Working with veterinarians to establish testing schedules and protocols ensures effective surveillance. Deciding on program goals, whether complete eradication or prevalence reduction, guides management intensity. Implementing colostrum and milk management protocols appropriate to the operation prevents new infections. Coordinating CAE management with other herd health activities improves efficiency. Establishing clear policies for management of positive animals ensures consistent decision-making. Regular program review assesses progress and identifies areas for improvement.

Record keeping and monitoring systems support effective CAE management over time. Individual animal identification enables tracking of test results, clinical status, and management decisions. Recording test dates and results for each animal documents herd status and program progress. Tracking offspring of positive and negative dams demonstrates program effectiveness. Documenting colostrum and milk management practices ensures protocol compliance. Recording clinical observations supports veterinary consultation and informs culling decisions. Maintaining movement records helps trace potential exposures if new infections are detected. Electronic record systems facilitate analysis and reporting.

Economic considerations for CAE management include the costs of testing, milk management, and potentially maintaining separate herds versus the benefits of disease control. Testing costs vary by method and laboratory but represent ongoing investment in control programs. Heat-treating colostrum or purchasing milk replacer adds cost to kid rearing but is essential for raising CAE-negative replacement stock. Maintaining separate groups for positive and negative animals may require additional facilities or management labor. The economic benefits of control programs include improved milk production, longer productive lives, and premium prices available for animals from certified CAE-negative herds. For breeding stock operations, CAE-negative status may be essential for sales to quality-conscious buyers.

High-risk breeds for CAE infection include dairy goat breeds that are commonly raised in intensive management systems where transmission opportunities are greatest. Saanen, Alpine, and Toggenburg breeds are frequently reported with high CAE prevalence, though this reflects management practices as much as genetic susceptibility. LaMancha and Nubian dairy breeds also show high prevalence in survey studies. Nigerian Dwarf goats have shown variable prevalence depending on management and testing practices. Essentially all goat breeds appear susceptible to infection when exposed, and the apparent differences in breed prevalence largely reflect differences in management intensity and historical exposure rather than genetic resistance.

Production type considerations significantly influence CAE prevalence and impact. Dairy goat operations typically show higher prevalence than meat goat operations due to management practices that favor transmission, particularly pooled colostrum feeding and prolonged kid rearing. Intensive dairy systems with high animal density provide numerous transmission opportunities. Show goats may have elevated risk due to congregation with animals of unknown status and the practice of purchasing animals from multiple sources. Fiber goats including Angora and Cashmere breeds can be infected but may have lower prevalence in extensively managed herds. Meat goat operations using extensive range management typically have lower prevalence due to reduced transmission opportunities.

Genetic selection and testing offer tools for reducing CAE impact within breeding programs. While no genetic markers for CAE resistance have been identified, selecting for animals from CAE-negative bloodlines avoids perpetuating infection through breeding programs. Testing all breeding stock before use ensures that only negative animals contribute genetics to the next generation. Some breeding programs have achieved complete elimination of CAE through rigorous testing and management over multiple generations. Artificial insemination using semen from tested-negative bucks provides an alternative to natural breeding when maintaining separation between positive and negative animals is difficult. Embryo transfer from negative donors allows genetic advancement while maintaining disease-free status.

Commonly co-occurring conditions with CAE reflect both the immunocompromising effects of lentivirus infection and the consequences of chronic debilitating disease. Secondary bacterial infections may occur with increased frequency in CAE-positive animals due to altered immune function. Caseous lymphadenitis often occurs in the same herds and may cause diagnostic confusion with the pneumonic form of CAE. Mycoplasma infections may complicate the clinical picture, particularly in herds with multiple respiratory pathogens. Parasitic burdens may be heavier in immunocompromised CAE-positive animals. Poor body condition associated with advanced disease increases susceptibility to various opportunistic infections.

Conditions with similar symptoms that must be differentiated from CAE include multiple other diseases affecting joints, nervous system, and respiratory tract. Mycoplasma arthritis causes joint swelling and lameness that resembles CAE arthritis but typically affects younger animals and may respond to appropriate antibiotic therapy. Bacterial septic arthritis produces acute joint swelling with systemic illness. Trauma can cause joint swelling but history usually reveals the inciting event. For neurological signs, listeriosis produces cranial nerve deficits unlike the ascending paralysis of CAE encephalitis. Polioencephalomalacia causes blindness and seizures. For respiratory signs, bacterial pneumonia and lungworm infection must be considered.

Complications and sequelae of CAE stem from the progressive, incurable nature of the disease. Arthritic animals develop progressive joint damage leading to increasing disability and eventual inability to ambulate. Muscle wasting secondary to disuse compounds mobility problems. Pressure sores develop in recumbent animals unable to rise. Mastitic udders become progressively harder, eventually rendering animals unsuitable for dairy production. Respiratory function declines in animals with pneumonic involvement. The fundamental long-term complication is progressive decline in quality of life that eventually necessitates humane euthanasia. At the herd level, failure to implement control programs results in ongoing transmission and progressive increase in clinical disease burden over time.